ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ATRI ATRION Corporation

415.08
0.13 (0.03%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
ATRION Corporation NASDAQ:ATRI NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.13 0.03% 415.08 320.00 420.00 426.45 415.08 422.46 36,896 22:30:00

Atrion Reports Third Quarter 2022 Results

08/11/2022 9:00pm

GlobeNewswire Inc.


ATRION (NASDAQ:ATRI)
Historical Stock Chart


From May 2022 to May 2024

Click Here for more ATRION Charts.

Atrion Corporation (NASDAQ: ATRI) today announced its results for the third quarter ended September 30, 2022.

Revenues for the third quarter of 2022 totaled $44.6 million compared to $42.9 million for the same period in 2021. For the quarter ended September 30, 2022, operating income was $9.6 million, up $125 thousand over the comparable 2021 period, and net income was $8.8 million, up $562 thousand over the same period in 2021. Third quarter 2022 diluted earnings per share were $4.94 compared to $4.58 for the third quarter of 2021.

Commenting on the results for the third quarter of 2022 compared to the prior year period, David Battat, President and CEO, stated, “Even with the impact of Hurricane Ian, revenues were up 4%, resulting in the highest revenues of any third quarter in our history. Net income and earnings per share were up by 7% and 8%, respectively. Continuing manufacturing cost increases lowered gross profit margins in the quarter from 42% to 40%."

Mr. Battat continued, “Thankfully, our employees and our Florida facility were not harmed by the hurricane, but $1.7 million in products scheduled for shipment from that facility the last week of the just ended quarter did not ship until October because trucking companies did not make scheduled pickups in the days leading up to the storm. We also incurred costs due to shutting down that facility for almost three days to ensure the safety of our employees.”

Updating expectations for the second half of 2022, Mr. Battat stated, “Our international customers are expressing greater concern about a severe recession in Europe, especially in light of inflationary pressures from winter energy prices. These customers have cautioned they may push out orders previously scheduled to ship at the end of this year into 2023. We expect revenues and operating income will still show gains, but at lower than previously projected levels.”

Mr. Battat concluded, “Cash and short and long term investments totaled $58.6 million at September 30, 2022 after our purchase of 8,577 shares of the Company’s stock during the third quarter at an average price of $593.46. We remain debt free.”

Atrion Corporation develops and manufactures products primarily for medical applications. The Company’s website is www.atrioncorp.com.

Statements in this press release that are forward looking are based upon current expectations and actual results or future events may differ materially.  Such statements include, but are not limited to, the Company’s expectations regarding revenues and operating income. Words such as "expects," "believes," "anticipates," "forecasts," "intends," "should", "plans," "will" and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements contained herein involve numerous risks and uncertainties, and there are a number of factors that could cause actual results or future events to differ materially, including, but not limited to, the following: the risk that the COVID-19 pandemic continues to lead to material delays and cancellations of, or reduced demand for, procedures in which our products are utilized; curtailed or delayed capital spending by hospitals and other healthcare providers; disruption to our supply chain; closures of our facilities; delays in training; delays in gathering clinical evidence; diversion of management and other resources to respond to the COVID-19 outbreak; the impact of global and regional economic and credit market conditions on healthcare spending; the risk that the COVID-19 virus continues to disrupt local economies and to cause economies in our key markets to enter prolonged recessions; changing economic, market and business conditions; acts of war or terrorism; the effects of governmental regulation; the impact of competition and new technologies; slower-than-anticipated introduction of new products or implementation of marketing strategies; implementation of new manufacturing processes or implementation of new information systems; our ability to protect our intellectual property; changes in the prices of raw materials; changes in product mix; intellectual property and product liability claims and product recalls; the ability to attract and retain qualified personnel; and the loss of, or any material reduction in sales to, any significant customers. In addition, assumptions relating to budgeting, marketing, product development and other management decisions are subjective in many respects and thus susceptible to interpretations and periodic review which may cause us to alter our marketing, capital expenditures or other budgets, which in turn may affect our results of operations and financial condition. The foregoing list of factors is not exclusive, and other factors are set forth in the Company's filings with the Securities and Exchange Commission. The forward-looking statements in this press release are made as of the date hereof, and we do not undertake any obligation, and disclaim any duty, to supplement, update or revise such statements, whether as a result of subsequent events, changed expectations or otherwise, except as required by applicable law.    

Contact:

Jeffery StricklandVice President and Chief Financial Officer(972) 390-9800

ATRION CORPORATIONUNAUDITED CONSOLIDATED STATEMENTS OF INCOME(In thousands, except per share data)

 Three Months EndedSeptember 30, Nine Months EndedSeptember 30,
  2022   2021   2022   2021 
Revenues$44,631  $42,855  $140,651  $124,716 
Cost of goods sold 26,978   25,065   82,921   72,720 
Gross profit 17,653   17,790   57,730   51,996 
Operating expenses 8,050   8,312   26,848   23,792 
Operating income 9,603   9,478   30,882   28,204 
        
Interest and dividend income  210   281    639    680 
Other investment income (loss)  764   (173)   216    852 
Other income  7    --    92    67 
Income before income taxes 10,584   9,586   31,829   29,803 
Income tax provision (1,745)  (1,309)  (5,143)  (4,875)
Net income $8,839  $8,277  $26,686  $24,928 
        
Income per basic share$4.95  $4.59  $14.89  $13.71 
        
Weighted average basic shares outstanding 1,786   1,803   1,793   1,818 
        
        
Income per diluted share$4.94  $4.58  $14.86  $13.68 
        
Weighted average diluted shares outstanding 1,788   1,806   1,796   1,822 
                

ATRION CORPORATIONCONSOLIDATED BALANCE SHEETS(In thousands)

 Sept. 30, Dec. 31,
ASSETS 2022  2021
 (Unaudited)  
Current assets:   
Cash and cash equivalents$27,125 $32,264
Short-term investments 20,296  29,059
Total cash and short-term investments 47,421  61,323
Accounts receivable 22,038  21,023
Inventories 59,624  50,778
Prepaid expenses and other 3,598  3,447
Total current assets 132,681  136,571
Long-term investments 11,133  19,423
Property, plant and equipment, net 115,113  97,972
Other assets 13,027  13,298
    
 $271,954 $267,264
    
    
LIABILITIES AND STOCKHOLDERS’ EQUITY   
    
Current liabilities 17,879  13,346
Line of credit --  --
Other non-current liabilities 7,800  9,622
Stockholders’ equity 246,275   244,296
    
 $271,954 $267,264

 

1 Year ATRION Chart

1 Year ATRION Chart

1 Month ATRION Chart

1 Month ATRION Chart

Your Recent History

Delayed Upgrade Clock